http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2791199-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97e93c996b129e56a24567f62a67afe1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2015-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c5a8a7fe94eb7a95a6d48845ea073e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef33e4a1b4d73f6cefc005a0ab522a86 |
| publicationDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2791199-T3 |
| titleOfInvention | Identification of cancer stem cell markers and their use for diagnosis and treatment |
| abstract | A method of identifying cancer stem cell markers in a human primary tumor comprising: (a) passage of the primary tumor in vivo to an immunodeficient non-human animal, wherein the cells from the primary tumor and the cells undergoing tumor passage primary do not undergo immunoisolation; and (b) comparing a level of at least one antigen in a first population of passaged tumor cells from the primary tumor with a second population of tumor cells from the primary tumor wherein said first population of passaged tumor cells is passaged. in vivo for at least 10 passages, wherein said second population of tumor cells are: (i) unpassed cells of the human primary tumor; or (ii) in vivo passaged cells of the human primary tumor, wherein said second population of tumor cells has been passaged in vivo for at least fewer passages than said first population of passaged tumor cells, in wherein an increase in the amount of said antigen in said first tumor cell population compared to the amount of said antigen in said second tumor cell population is indicative of a cancer stem cell marker in the human primary tumor. |
| priorityDate | 2014-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 803.